HB 524 – Oral Chemo Treatment Access During Pandemic

HB 524 – Oral Chemo Treatment Access During Pandemic

Primary House Sponsors: Rep. Carla Cunningham (D-Mecklenburg); Rep. Gale Adcock (D-Wake); Rep. Wayne Sasser (R-Cabarrus, Rowan, Stanly)

Summary

This bill requires health benefit plans that provide coverage for prescribed, orally administered anticancer drugs and for intravenously administered or injected anticancer drugs to: (1) provide coverage for prescribed, orally administered anticancer drugs on a basis no less favorable than the coverage the plan provides for intravenously administered; and (2) provide coverage for orally administered anticancer drugs that is not subject to any prior authorization, dollar limit, copayment, coinsurance, or deductible provision or to any other out-of-pocket expense that does not apply to intravenously administered or injected anticancer drugs.

This bill also prohibits health benefit plans from achieving compliance with these requirements by reclassifying anticancer drugs or by increasing patient cost-sharing imposed on anticancer drugs.

Movement

Filed – 4/8/2021